Updates are available Correction dated 2024-02-15
Click to view Correction: https://doi.org/10.1038/s41590-024-01781-5
-
Authors
Ying, Baoling
Darling, Tamarand L.
Desai, Pritesh https://orcid.org/0000-0002-4697-9475
Liang, Chieh-Yu https://orcid.org/0000-0003-4624-7212
Dmitriev, Igor P. https://orcid.org/0000-0001-9206-1975
Soudani, Nadia
Bricker, Traci
Kashentseva, Elena A.
Harastani, Houda https://orcid.org/0000-0002-1234-6194
Raju, Saravanan
Liu, Meizi
Schmidt, Aaron G. https://orcid.org/0000-0003-3627-2553
Curiel, David T. https://orcid.org/0000-0003-3802-6014
Boon, Adrianus C. M. https://orcid.org/0000-0002-4700-8224
Diamond, Michael S. https://orcid.org/0000-0002-8791-3165
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01 AI157155, HHSN272201400008C, 75N93021C00014, R01 AI146779, R01 CA211096, 75N93021C00016)
- License Information
-
More Information
Article History
Received: 13 July 2023
Accepted: 8 January 2024
First Online: 9 February 2024
Change Date: 15 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-024-01781-5
Competing interests
: M.S.D. is a consultant for Inbios, Vir Biotechnology, Ocugen, IntegerBio, GlaxoSmithKline, Allen & Overy LLP, Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions and Moderna. The Boon laboratory has received unrelated funding support in sponsored research agreements from GreenLight Biosciences, Inc. The Boon laboratory has received funding support from AbbVie, Inc., for the commercial development of SARS-CoV-2 monoclonal antibody and Moderna for unrelated work. D.T.C. is a consultant for Ocugen, Circero, Asgard, Accession and Tome Biosciences. M.S.D., D.T.C. and I.P.D. are inventors of the ChAd-SARS-CoV-2 technology, which Washington University has licensed to Bharat Biotech and Ocugen for commercial development. The other authors declare no competing interests.
